Postinflammatory hyperpigmentation
Postinflammatory hyperpigmentation on nahahaigus, mida iseloomustab nahapõletiku tagajärjel suurenenud pigment nahas. Postinflammatory hyperpigmentation võib põhjustada pikaajaline päikese käes viibimine, põletik või muud nahavigastused, sealhulgas aknega seotud vigastused. Tumedama nahatooniga inimesed on tavaliselt altid hüperpigmentatsioonile liigse päikese käes.
☆ Saksamaa 2022. aasta Stiftung Warentesti tulemustes oli tarbijate rahulolu ModelDermiga vaid veidi madalam kui tasuliste telemeditsiini konsultatsioonidega.
References
Postinflammatory hyperpigmentation (PIH) on sagedane nahaprobleem, mis tekib pärast nahapõletikku või vigastust. See kipub kestma kaua ja on hullem tumedama nahatooniga inimestel (Fitzpatrick skin types III–VI) . Kuigi see paraneb sageli iseenesest, võib see veidi aega võtta, mistõttu on sageli vaja ravi pikka aega. Erinevate ravimeetodite kombineerimine toimib kõige paremini.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation on nahapõletiku tavaline tagajärg. See mõjutab tumedama nahaga inimesi tugevamalt ja sagedamini. Uuringud näitavad, et sellised probleemid nagu postinflammatory hyperpigmentation on üks peamisi põhjuseid, miks tumedama nahatooniga inimesed otsivad dermatoloogilist abi. Varajane ravi on postinflammatory hyperpigmentation lahendamisel otsustava tähtsusega ja algab tavaliselt esialgse põletikulise seisundi juhtimisega. Esimene raviliin hõlmab tavaliselt nahka kergendavate paiksete ainete kasutamist koos päikesekaitsekreemiga. Need ained, nagu hydroquinone, azelaic acid, kojic acid, arbutin, licorice extracts , võivad tõhusalt vähendada liigset pigmentatsiooni. Lisaks kasutatakse retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, soy ka depigmenteerivate ainetena, kusjuures esile kerkivad uued ravimeetodid. Kuigi paiksed ravimeetodid on tavaliselt efektiivsed pinnataseme hüperpigmentatsiooni korral, võivad kangekaelsete juhtumite korral olla vajalikud protseduurid (laser, chemical peel) . Nende ravimeetodite puhul on oluline olla ettevaatlik, et vältida ärritust ja postinflammatory hyperpigmentation süvenemist.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
